Synergistic Action of Gentamicin and Bacteriophage in a Continuous Culture Population of Staphylococcus aureus

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Kirby, Amy E ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENTAMICIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL STRAIN; BACTERIOPHAGE; BACTERIUM CULTURE; BIOFILM; CELL AGGREGATION; CELL POPULATION; COMPUTER MODEL; CULTURE TECHNIQUE; DRUG EFFICACY; DRUG TARGETING; MICROBIAL POPULATION DYNAMICS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHARMACODYNAMICS; PHARMACOKINETICS; PHENOTYPE; SIMULATION; STAPHYLOCOCCUS AUREUS;

ADSORPTION; BACTERIOPHAGES; CELL CULTURE TECHNIQUES; COMPUTER SIMULATION; GENTAMICINS; MODELS, BIOLOGICAL; PHENOTYPE; STAPHYLOCOCCUS AUREUS; VIRUS REPLICATION;

STAPHYLOCOCCUS AUREUS;

EID: 84870606574     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051017     Document Type: Article

References (64)

1. Sulakvelidze A, Alavidze Z, Morris JG, (2001) Bacteriophage therapy. Antimicrobial agents and chemotherapy 45: 649-659.
2. Meader E, Mayer MJ, Gasson MJ, Steverding D, Carding SR, et al. (2010) Bacteriophage treatment significantly reduces viable Clostridium difficile and prevents toxin production in an in vitro model system. Anaerobe 16: 549-554.
3. Sillankorva S, Oliveira D, Moura A, Henriques M, Faustino A, et al. (2011) Efficacy of a broad host range lytic bacteriophage against E. coli adhered to urothelium. Current microbiology 62: 1128-1132.
4. Letkiewicz S, Miedzybrodzki R, Klak M, Jonczyk E, Weber-Dabrowska B, et al. (2010) The perspectives of the application of phage therapy in chronic bacterial prostatitis. FEMS immunology and medical microbiology 60: 99-112.
5. Kumari S, Harjai K, Chhibber S, (2011) Bacteriophage versus antimicrobial agents for the treatment of murine burn wound infection caused by Klebsiella pneumoniae B5055. Journal of medical microbiology 60: 205-210.
6. Tothova L, Celec P, Babickova J, Gajdosova J, Al-Alami H, et al. (2011) Phage therapy of Cronobacter-induced urinary tract infection in mice. Medical science monitor: international medical journal of experimental and clinical research 17: BR173-178.
7. Gu J, Liu X, Li Y, Han W, Lei L, et al. (2012) A method for generation phage cocktail with great therapeutic potential. PLoS One 7: e31698.
8. Morello E, Saussereau E, Maura D, Huerre M, Touqui L, et al. (2011) Pulmonary bacteriophage therapy on Pseudomonas aeruginosa cystic fibrosis strains: first steps towards treatment and prevention. PLoS One 6: e16963.
9. Wright A, Hawkins CH, Anggard EE, Harper DR, (2009) A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clinical otolaryngology: official journal of ENT-UK; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery 34: 349-357.
10. Coffey B, Mills S, Coffey A, McAuliffe O, Ross RP, (2010) Phage and their lysins as biocontrol agents for food safety applications. Annual review of food science and technology 1: 449-468.
11. Atterbury RJ, (2009) Bacteriophage biocontrol in animals and meat products. Microbial biotechnology 2: 601-612.
12. Galvez A, Abriouel H, Benomar N, Lucas R, (2010) Microbial antagonists to food-borne pathogens and biocontrol. Current opinion in biotechnology 21: 142-148.
13. Roy B, Ackermann HW, Pandian S, Picard G, Goulet J, (1993) Biological inactivation of adhering Listeria monocytogenes by listeriaphages and a quaternary ammonium compound. Applied and environmental microbiology 59: 2914-2917.
14. Abuladze T, Li M, Menetrez MY, Dean T, Senecal A, et al. (2008) Bacteriophages reduce experimental contamination of hard surfaces, tomato, spinach, broccoli, and ground beef by Escherichia coli O157:H7. Applied and environmental microbiology 74: 6230-6238.
15. Guenther S, Huwyler D, Richard S, Loessner MJ, (2009) Virulent bacteriophage for efficient biocontrol of Listeria monocytogenes in ready-to-eat foods. Applied and environmental microbiology 75: 93-100.
16. Moradpour Z, Ghasemian A, (2011) Modified phages: novel antimicrobial agents to combat infectious diseases. Biotechnology advances 29: 732-738.
17. Lu TK, Koeris MS, (2011) The next generation of bacteriophage therapy. Current opinion in microbiology 14: 524-531.
18. Loc-Carrillo C, Abedon ST, (2011) Pros and cons of phage therapy. Bacteriophage 1: 111-114.
19. Huff WE, Huff GR, Rath NC, Donoghue AM, (2010) Immune interference of bacteriophage efficacy when treating colibacillosis in poultry. Poultry science 89: 895-900.
20. Chao L, Levin BR, Stewart FM, (1977) Complex Community in a Simple Habitat- Experimental-Study with Bacteria and Phage. Ecology 58: 369-378.
21. Lenski RE, Levin BR, (1985) Constraints on the Coevolution of Bacteria and Virulent Phage- a Model, Some Experiments, and Predictions for Natural Communities. American Naturalist 125: 585-602.
22. Bohannan BJM, Lenski RE, (2000) Linking genetic change to community evolution: insights from studies of bacteria and bacteriophage. Ecology Letters 3: 362-377.
23. Korona R, Levin BR, (1993) Phage-Mediated Selection and the Evolution and Maintenance of Restriction-Modification. Evolution 47: 556-575.
24. Levin BR, Bull JJ, (2004) Population and evolutionary dynamics of phage therapy. Nature reviews Microbiology 2: 166-173.
25. Edgar R, Friedman N, Molshanski-Mor S, Qimron U, (2012) Reversing bacterial resistance to antibiotics by phage-mediated delivery of dominant sensitive genes. Applied and environmental microbiology 78: 744-751.
26. Lu TK, Collins JJ, (2009) Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy. Proceedings of the National Academy of Sciences of the United States of America 106: 4629-4634.
27. Vaks L, Benhar I, (2011) In vivo characteristics of targeted drug-carrying filamentous bacteriophage nanomedicines. Journal of nanobiotechnology 9: 58.
28. Lu TK, Collins JJ, (2007) Dispersing biofilms with engineered enzymatic bacteriophage. Proceedings of the National Academy of Sciences of the United States of America 104: 11197-11202.
29. Verma V, Harjai K, Chhibber S, (2010) Structural changes induced by a lytic bacteriophage make ciprofloxacin effective against older biofilm of Klebsiella pneumoniae. Biofouling 26: 729-737.
30. Rahman M, Kim S, Kim SM, Seol SY, Kim J, (2011) Characterization of induced Staphylococcus aureus bacteriophage SAP-26 and its anti-biofilm activity with rifampicin. Biofouling 27: 1087-1093.
31. Jalasvuori M, Friman VP, Nieminen A, Bamford JK, Buckling A, (2011) Bacteriophage selection against a plasmid-encoded sex apparatus leads to the loss of antibiotic-resistance plasmids. Biology letters 7: 902-905.
32. Comeau AM, Tetart F, Trojet SN, Prere MF, Krisch HM, (2007) Phage-Antibiotic Synergy (PAS): beta-lactam and quinolone antibiotics stimulate virulent phage growth. PLoS One 2: e799.
33. Burrowes B, Harper DR, Anderson J, McConville M, Enright MC, (2011) Bacteriophage therapy: potential uses in the control of antibiotic-resistant pathogens. Expert review of anti-infective therapy 9: 775-785.
34. Partridge SR, (2011) Analysis of antibiotic resistance regions in Gram-negative bacteria. FEMS microbiology reviews 35: 820-855.
35. Verma V, Harjai K, Chhibber S, (2009) Restricting ciprofloxacin-induced resistant variant formation in biofilm of Klebsiella pneumoniae B5055 by complementary bacteriophage treatment. The Journal of antimicrobial chemotherapy 64: 1212-1218.
36. (2005) Performance Standards for Antimicrobial Susceptibility Testing. Fifteenth Informational Supplement. Wayne, PA: CLSI.
37. Kropinski AM, (2009) Measurement of the rate of attachment of bacteriophage to cells. Methods in molecular biology 501: 151-155.
38. Hyman P, Abedon ST, (2009) Practical methods for determining phage growth parameters. Methods in molecular biology 501: 175-202.
39. Udekwu KI, Levin BR, (2012) Staphylococcus aureus in Continuous Culture: A Tool for the Rational Design of Antibiotic Treatment Protocols. PLoS One 7: e38866.
40. O'Toole GA, Kolter R, (1998) Initiation of biofilm formation in Pseudomonas fluorescens WCS365 proceeds via multiple, convergent signalling pathways: a genetic analysis. Molecular microbiology 28: 449-461.
41. Vandersteegen K, Mattheus W, Ceyssens PJ, Bilocq F, De Vos D, et al. (2011) Microbiological and molecular assessment of bacteriophage ISP for the control of Staphylococcus aureus. PLoS One 6: e24418.
42. Levin BR, Udekwu KI, (2010) Population dynamics of antibiotic treatment: a mathematical model and hypotheses for time-kill and continuous-culture experiments. Antimicrob Agents Chemother 54: 3414-3426.
43. Regoes RR, Wiuff C, Zappala RM, Garner KN, Baquero F, et al. (2004) Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens. Antimicrobial agents and chemotherapy 48: 3670-3676.
44. Haaber J, Cohn MT, Frees D, Andersen TJ, Ingmer H, (2012) Planktonic Aggregates of Staphylococcus aureus Protect against Common Antibiotics. PLoS One 7: e41075.
45. Schroeder K, Jularic M, Horsburgh SM, Hirschhausen N, Neumann C, et al. (2009) Molecular characterization of a novel Staphylococcus aureus surface protein (SasC) involved in cell aggregation and biofilm accumulation. PLoS One 4: e7567.
46. Fedtke I, Mader D, Kohler T, Moll H, Nicholson G, et al. (2007) A Staphylococcus aureus ypfP mutant with strongly reduced lipoteichoic acid (LTA) content: LTA governs bacterial surface properties and autolysin activity. Molecular microbiology 65: 1078-1091.
47. Holland LM, Conlon B, O'Gara JP, (2011) Mutation of tagO reveals an essential role for wall teichoic acids in Staphylococcus epidermidis biofilm development. Microbiology 157: 408-418.
48. Wagstaff JL, Sadovskaya I, Vinogradov E, Jabbouri S, Howard MJ, (2008) Poly-N-acetylglucosamine and poly(glycerol phosphate) teichoic acid identification from staphylococcal biofilm extracts using excitation sculptured TOCSY NMR. Molecular bioSystems 4: 170-174.
49. Kusser W, Zimmer K, Fiedler F, (1985) Characteristics of the binding of aminoglycoside antibiotics to teichoic acids. A potential model system for interaction of aminoglycosides with polyanions. European journal of biochemistry/FEBS 151: 601-605.
50. Xia G, Maier L, Sanchez-Carballo P, Li M, Otto M, et al. (2010) Glycosylation of wall teichoic acid in Staphylococcus aureus by TarM. The Journal of biological chemistry 285: 13405-13415.
51. Wendlinger G, Loessner MJ, Scherer S, (1996) Bacteriophage receptors on Listeria monocytogenes cells are the N-acetylglucosamine and rhamnose substituents of teichoic acids or the peptidoglycan itself. Microbiology 142 (Pt 4): 985-992.
52. Haberer K, Maniloff J, (1982) Adsorption of the tailed mycoplasma virus L3 to cell membranes. Journal of virology 41: 501-507.
53. Heller K, Braun V, (1979) Accelerated adsorption of bacteriophage T5 to Escherichia coli F, resulting from reversible tail fiber-lipopolysaccharide binding. Journal of bacteriology 139: 32-38.
54. Kropinski AM, Warren RA, (1970) Isolation and properties of a Pseudomonas acidovorans bacteriophage. The Journal of general virology 6: 85-93.
55. Incardona NL, Selvidge L, (1973) Mechanism of adsorption and eclipse of bacteriophage phi X174. II. Attachment and eclipse with isolated Escherichia coli cell wall lipopolysaccharide. Journal of virology 11: 775-782.
56. Merabishvili M, Pirnay JP, Verbeken G, Chanishvili N, Tediashvili M, et al. (2009) Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS One 4: e4944.
57. Bohannan BJM, Kerr B, Jessup CM, Hughes JB, Sandvik G, (2002) Trade-offs and coexistence in microbial microcosms. Antonie Van Leeuwenhoek International Journal of General and Molecular Microbiology 81: 107-115.
58. Ljungh A, Hjerten S, Wadstrom T, (1985) High surface hydrophobicity of autoaggregating Staphylococcus aureus strains isolated from human infections studied with the salt aggregation test. Infection and immunity 47: 522-526.
59. Cushnie TP, Hamilton VE, Chapman DG, Taylor PW, Lamb AJ, (2007) Aggregation of Staphylococcus aureus following treatment with the antibacterial flavonol galangin. Journal of applied microbiology 103: 1562-1567.
60. Lin KC, Chen CY, Chang CW, Huang KJ, Lin SP, et al. (2012) A dodecapeptide (YQVTQSKVMSHR) exhibits antibacterial effect and induces cell aggregation in Escherichia coli. Applied microbiology and biotechnology 94: 755-762.
61. Andersen MT, Brondsted L, Pearson BM, Mulholland F, Parker M, et al. (2005) Diverse roles for HspR in Campylobacter jejuni revealed by the proteome, transcriptome and phenotypic characterization of an hspR mutant. Microbiology 151: 905-915.
62. Frick IM, Morgelin M, Bjorck L, (2000) Virulent aggregates of Streptococcus pyogenes are generated by homophilic protein-protein interactions. Molecular microbiology 37: 1232-1247.
63. Alhede M, Kragh KN, Qvortrup K, Allesen-Holm M, van Gennip M, et al. (2011) Phenotypes of non-attached Pseudomonas aeruginosa aggregates resemble surface attached biofilm. PLoS One 6: e27943.
64. Bjarnsholt T, Jensen PO, Fiandaca MJ, Pedersen J, Hansen CR, et al. (2009) Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Pediatric pulmonology 44: 547-558.